Related references
Note: Only part of the references are listed.Lipid-lowering agents and new onset diabetes mellitus
Vasilios G. Athyros et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study
Bernard Zinman et al.
LANCET (2010)
Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
John J. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study
G. A. Bray et al.
LANCET (2009)
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance
Ryuzo Kawamori et al.
LANCET (2009)
Meta-analysis: Metformin treatment in persons at risk for diabetes mellitus
Shelley R. Salpeter et al.
AMERICAN JOURNAL OF MEDICINE (2008)
Prevention of Diabetes in Women with a History of Gestational Diabetes: Effects of Metformin and Lifestyle Interventions
Robert E. Ratner et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study
Guangwei Li et al.
LANCET (2008)
Prevention of type 2 diabetes: A review
A. Hussain et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Impaired fasting glucose and impaired glucose tolerance - Implications for care
David M. Nathan et al.
DIABETES CARE (2007)
Physical activity of moderate intensity and risk of type 2 diabetes
Christie Y. Jeon et al.
DIABETES CARE (2007)
Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention:: follow-up of the Finnish Diabetes Prevention Study
Jaana Lindstrom et al.
LANCET (2006)
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:: a randomised controlled trial
H. C. Gerstein et al.
LANCET (2006)
Effect of weight loss with lifestyle intervention on risk of diabetes
Richard F. Hamman et al.
DIABETES CARE (2006)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients
A Tenenbaum et al.
EUROPEAN HEART JOURNAL (2005)
The impart of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes
EL Gillespie et al.
DIABETES CARE (2005)
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
L Sjöström et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system
AJ Scheen
DRUGS (2004)
XENical in the prevention of diabetes in obese subjects (XENDOS) study
JS Torgerson et al.
DIABETES CARE (2004)
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease
A Tenenbaum et al.
CIRCULATION (2004)
Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030
S Wild et al.
DIABETES CARE (2004)
Surgery as an intervention for obesity.: Results from the Swedish obese subjects study
CD Sjöström
GROWTH HORMONE & IGF RESEARCH (2003)
Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition
EJ Henriksen et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2003)
Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease
SI McFarlane et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001
AH Mokdad et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women
TA Buchanan et al.
DIABETES (2002)
Metformin: An update
D Kirpichnikov et al.
ANNALS OF INTERNAL MEDICINE (2002)
Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes
FB Hu et al.
DIABETES CARE (2002)
Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial
JL Chiasson et al.
LANCET (2002)
Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers
SI McFarlane et al.
DIABETES CARE (2002)
Clinical review 145 - Pleiotropic effects of statins: Lipid reduction and beyond
SI McFarlane et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol
LH Lindholm et al.
LANCET (2002)
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
WC Knowler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Ramipril and the development of diabetes
S Yusuf et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
J Tuomilehto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Diabetes, hypertension, and cardiovascular disease - An update
JR Sowers et al.
HYPERTENSION (2001)
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults
SB Heymsfield et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
